| I N TR ODU C TI ON
As every practicing genetics professional faced with a variant of unknown significance knows, the lack of diversity in large genomic datasets can hamstring clinical care (Bustamante, Burchard, & De la Vega, 2011; Need & Goldstein, 2009; Popejoy & Fullerton, 2016) . The dearth of persons of non-European ancestry in genomic datasets limits researchers' ability to characterize the full spectrum of genetic diversity, ultimately leading to increased risk of mischaracterization of genetic variants and misdiagnosis for more than 75% of the world's population. Reports documenting the misclassification of benign hypertrophic cardiomyopathy variants in African Americans represent only one of several recent cases that highlight this hazard (Grady, 2016; Howard, 2016; Manrai et al., 2016) . In order to be able to provide the most informed care to every patient, we must find ways to engage with and actively encourage the participation of the broadest spectrum of persons in genomic research.
In the United States, the diversity of genomic datasets hinges on overcoming the twin legacy of disenfranchisement and mistreatment of non-white populations by the research community (Corbie-Smith, Thomas, & St. George, 2002; Joseph & Dohan, 2009; van Ryn & Burke, 2000) . Hindorff and colleagues call for diversity to be taken into consideration at all stages of the research process from initial study design, to data analysis, to dissemination of results (Hindorff et al., 2017) . As the entry point for all prospective participants into research, the informed consent process merits similar attention.
The informed consent process, which incorporates documentation as well as accompanying interactions and activities, is fundamental to the ethical practice of clinical research and is codified by an extensive patchwork of laws and regulations worldwide. As in many jurisdictions, the U.S. Common Rule (Federal Policy for the Protection of Human Subjects, 45 CFR part 46) requires the consent process to enable prospective participants' autonomous decision making (45 CFR 46.116) .
Unfortunately, traditional written consent forms are often dense, wordy, and legalistic, and the consenting process is often rushed (Cassileth, Zupkis, Sutton-Smith, & March, 1980; Paasche-Orlow, Taylor, & Brancati, 2003) . Consequently, for many individuals, informed consent is not actually supportive of their decision making. For example, Flory and Emanuel analyzed 30 studies of participant understanding following informed consent in clinical trial settings, deeming participant understanding of key elements of informed consent adequate in only about half of the studies they reviewed (Flory & Emanuel, 2004) . In a subsequent review, Montalvo and Larson identified risk factors for poor informedness, including low literacy, low educational attainment, and being a non-native English speaker (for studies conducted primarily in English) (Montalvo & Larson, 2014) . These findings are consistent with the 2003 National Assessment of Adult Literacy survey, which identified greater proportions of persons with below basic health literacy among adults with less than a high school education; individuals identifying as Hispanic/Latino, American Indian/Alaska native, or black; uninsured individuals; and Medicare/Medicaid beneficiaries (Kutner, Greenberg, Jin, & Paulsen, 2006) .
The absence of culturally and linguistically appropriate documents is a critical barrier to recruiting diverse patient populations for many studies, as it can deter participation and lead to mistrust (Hughson et al., 2016) . To develop better and more effective informed consent processes, Dickert and colleagues recently suggested taking a contextualized approach that attends to the many overarching functions of consent. These include providing transparency and promoting values concordance on an individual level, and building trust on a community level (Dickert et al., 2017) . By developing informed consent processes The CHARM study offers an opportunity to develop and evaluate novel, patient-centered consent materials that are accessible to patients from a wide range of cultural and linguistic backgrounds. The study uses an innovative, multimedia consent process on a smartphone-optimized web interface, which is an approach that has potential to increase accessibility and streamline the consent process (Haussen et al., 2017) . The consent text, available in both English and Spanish (translated by a bilingual study team member), is written at approximately a fifth grade reading level and includes an audio option for patients who prefer to hear information rather than read. Because of the potential for multimedia to improve understanding of consent among low literacy populations (Afolabi et al., 2015) , each key point in the consent form is accompanied by a custom illustration developed by health communications media experts at Booster Shot Media (www.boostershotmedia.com). These illustrations use a gender-and race-neutral cartoon icon to provide a simple and consistent visual representation that each patient can identify with across different points in the consent process (Figure 1) .
Additionally, the CHARM study uses a contextualized consent process, meaning that it is designed to allow patients to make two separate decisions: whether they want genetic testing, and whether they want to join the study. The consent process first describes genetic testing for hereditary cancer, which is available clinically to most eligible patients regardless of whether they join the study. Those who show interest in testing can then review a study consent document that describes additional details about the study, including randomization between genetic counseling approaches, review of medical records, surveys and interviews, and data sharing. This approach encourages patients to differentiate between the two distinct decisions of whether they want to pursue testing and whether they want to join the CHARM study.
Throughout the design of recruitment, consent, and other patientfacing materials, CHARM study investigators are working with a patient advisory committee to iteratively provide feedback on process, design, language, and other study features. This committee of patients from CHARM's target population allows study investigators to ensure that attempts at increasing accessibility are truly responsive to patients' needs. As recruitment begins, the study will use a variety of qualitative and quantitative measures to evaluate patients' reactions to this novel consent process in practice.
| The All of Us Research Program
The All of Us Research Program, a keystone of the Precision Medicine Initiative, is a national research initiative that aims to assemble a cohort of one million or more people representative of the diversity of those way are essential tools to realizing greater diversity in genomic datasets. To the extent that they succeed in doing so, informed consent may be able to serve a second purpose in addition to enabling patients to make autonomous decisions about research: it may also contribute to the development of trusting, respectful research partnerships.
As these and other research efforts progress, it will be important to track recruitment and retention across different patient populations, as well as the effects on measures including trust, comprehension, and satisfaction with the consent process. We encourage the formation of an open community of practice to accelerate collective learning regarding novel approaches to informed consent to benefit the entire research ecosystem and to support the provision of high-quality clinical genetics care for all patients.
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